Health Professionals: More About CYP450 Genotyping and the Use of SSRI Drugs for Depression in Adults
This website is archived for historical purposes and is no longer being maintained or updated.
This page contains information that is not part of the EGAPP™ recommendation, but may be important for health professionals.
Major depressive disorder is the leading cause of disability in the United States, with a lifetime prevalence estimated as high as 16%. SSRI drugs are the first-line choice for treatment of depression. Public health practitioners may choose to use this EGAPP™ recommendation information to support the following public health activities:
- Dissemination of these Web-based materials and the EGAPP™ recommendation to partners and other groups to increase awareness of these resources.
- Using surveillance to assess the current usage of genetic testing for CYP450 variants to determine the need for targeted educational campaigns aimed at informing providers and the public about the EGAPP™ recommendations and limitations of CYP450 genetic testing.
Top of Page
- CYP450 genotyping performed for SSRI metabolism can also provide information on the metabolism of many other drugs for a variety of health conditions.
- CYP450 genetic testing is available through direct-to-consumer testing companies.
- Major Depressive Disorder, Diagnostic and Statistical Manual (DSM) of Mental Disorders, Fourth Edition, American Psychiatric Publishing
- DSM-IV Criteria for Major Depressive Episode and Major Depressive Disorder
- Depression, National Institutes of Health
- Center for Mental Health Services, SAMHSA
- Testing for Cytochrome P450 Polymorphisms in Adults with Non-Psychotic Depression Treated with Selective Serotonin Reuptake Inhibitors (SSRIs), AHRQ [944.37 KB]
- Second Generation Antidepressants, NCBI
- Page last reviewed: October 21, 2011 (archived document)
- Content source: